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Described decades ago, the Warburg effect of aerobic glycolysis is a key metabolic hallmark of 
cancer, yet its significance remains unclear. In this Essay, we re-examine the Warburg effect and 
establish a framework for understanding its contribution to the altered metabolism of cancer cells.It is hard to begin a discussion of cancer 
cell metabolism without first mentioning 
Otto Warburg. A pioneer in the study of 
respiration, Warburg made a striking dis-
covery in the 1920s. He found that, even 
in the presence of ample oxygen, cancer 
cells prefer to metabolize glucose by gly-
colysis, a seeming paradox as glycolysis, 
when compared to oxidative phosphory-
lation, is a less efficient pathway for pro-
ducing ATP (Warburg, 1956). The War-
burg effect has since been demonstrated 
in different types of tumors and the con-
comitant increase in glucose uptake has 
been exploited clinically for the detection 
of tumors by fluorodeoxyglucose posi-
tron emission tomography (FDG-PET). 
Although aerobic glycolysis has now 
been generally accepted as a metabolic 
hallmark of cancer, its causal relationship 
with cancer progression is still unclear. In 
this Essay, we discuss the possible driv-
ers, advantages, and potential liabilities 
of the altered metabolism of cancer cells 
(Figure 1). Although our emphasis on the 
Warburg effect reflects the focus of the 
field, we would also like to encourage a 
broader approach to the study of cancer 
metabolism that takes into account the 
contributions of all interconnected small 
molecule pathways of the cell.
The Tumor Microenvironment 
Selects for Altered Metabolism
One compelling idea to explain the War-
burg effect is that the altered metabo-
lism of cancer cells confers a selective 
advantage for survival and proliferation 
in the unique tumor microenvironment. 
As the early tumor expands, it outgrows 
the diffusion limits of its local blood sup-
ply, leading to hypoxia and stabilization 
of the hypoxia-inducible transcription 
factor, HIF. HIF initiates a transcrip-
tional program that provides multiple 
solutions to hypoxic stress (reviewed in 
Kaelin and Ratcliffe, 2008). Because a 
decreased dependence on aerobic res-
piration becomes advantageous, cell 
metabolism is shifted toward glycolysis 
by the increased expression of glyco-
lytic enzymes, glucose transporters, and 
inhibitors of mitochondrial metabolism. 
In addition, HIF stimulates angiogenesis 
(the formation of new blood vessels) by 
upregulating several factors, including 
most prominently vascular endothelial 
growth factor (VEGF).
Blood vessels recruited to the tumor 
microenvironment, however, are disor-
ganized, may not deliver blood effec-
tively, and therefore do not completely 
alleviate hypoxia (reviewed in Gatenby 
and Gillies, 2004). The oxygen levels 
within a tumor vary both spatially and 
temporally, and the resulting rounds 
of fluctuating oxygen levels potentially 
select for tumors that constitutively 
upregulate glycolysis. Interestingly, 
with the possible exception of tumors 
that have lost the von Hippel-Lindau 
protein (VHL), which normally mediates 
degradation of HIF, HIF is still coupled 
to oxygen levels, as evident from the 
heterogeneity of HIF expression within 
the tumor microenvironment (Wiesener 
et al., 2001; Zhong et al., 1999). There-
fore, the Warburg effect—that is, an 
uncoupling of glycolysis from oxygen 
levels—cannot be explained solely by 
upregulation of HIF. Other molecular 
mechanisms are likely to be important, 
such as the metabolic changes induced 
by oncogene activation and tumor sup-
pressor loss.
Oncogene Activation Drives 
Changes in Metabolism
Not only may the tumor microenviron-
ment select for a deranged metabolism, 
but oncogene status can also drive 
metabolic changes. Since Warburg’s 
time, the biochemical study of cancer 
metabolism has been overshadowed 
by efforts to identify the mutations 
that contribute to cancer initiation and 
progression. Recent work, however, 
has demonstrated that the key compo-
nents of the Warburg effect—increased 
glucose consumption, decreased oxi-
dative phosphorylation, and accom-
panying lactate production—are also 
distinguishing features of oncogene 
activation. The signaling molecule Ras, 
a powerful oncogene when mutated, 
promotes glycolysis (reviewed in Dang 
and Semenza, 1999; Ramanathan et al., 
2005). Akt kinase, a well-characterized 
downstream effector of insulin signaling, 
reprises its role in glucose uptake and 
utilization in the cancer setting (reviewed 
in Manning and Cantley, 2007), whereas 
the Myc transcription factor upregulates 
the expression of various metabolic 
genes (reviewed in Gordan et al., 2007). 
The most parsimonious route to tumori-
genesis may be activation of key onco-
genic nodes that execute a proliferative 
program, of which metabolism may be 
one important arm. Moreover, regula-
tion of metabolism is not exclusive to 
oncogenes. Loss of the tumor suppres-
sor protein p53 prevents expression of Cell 134, September 5, 2008 ©2008 Elsevier Inc. 703
Figure 1. The Altered Metabolism of Cancer Cells
Drivers (A and B). The metabolic derangements in cancer cells may arise either from the selection of cells that have adapted to the tumor microenvironment or 
from aberrant signaling due to oncogene activation. The tumor microenvironment is spatially and temporally heterogeneous, containing regions of low oxygen 
and low pH (purple). Moreover, many canonical cancer-associated signaling pathways induce metabolic reprogramming. Target genes activated by hypoxia-
inducible factor (HIF) decrease the dependence of the cell on oxygen, whereas Ras, Myc, and Akt can also upregulate glucose consumption and glycolysis. 
Loss of p53 may also recapitulate the features of the Warburg effect, that is, the uncoupling of glycolysis from oxygen levels.
Advantages (C–E). The altered metabolism of cancer cells is likely to imbue them with several proliferative and survival advantages, such as enabling cancer cells 
to execute the biosynthesis of macromolecules (C), to avoid apoptosis (D), and to engage in local metabolite-based paracrine and autocrine signaling (E).
Potential Liabilities (F and G). This altered metabolism, however, may also confer several vulnerabilities on cancer cells. For example, an upregulated metabo-
lism may result in the build up of toxic metabolites, including lactate and noncanonical nucleotides, which must be disposed of (F). Moreover, cancer cells may 
also exhibit a high energetic demand, for which they must either increase flux through normal ATP-generating processes, or else rely on an increased diversity 
of fuel sources (G).the gene encoding SCO2 (the synthesis 
of cytochrome c oxidase protein), which 
interferes with the function of the mito-
chondrial respiratory chain (Matoba et 
al., 2006). A second p53 effector, TIGAR 
(TP53-induced glycolysis and apop-
tosis regulator), inhibits glycolysis by 
decreasing levels of fructose-2,6-bis-
phosphate, a potent stimulator of glyc-
olysis and inhibitor of gluconeogenesis 
(Bensaad et al., 2006). Other work also 
suggests that p53-mediated regulation 
of glucose metabolism may be depen-
dent on the transcription factor NF-κB 
(Kawauchi et al., 2008).
It has been shown that inhibition of lac-
tate dehydrogenase A (LDH-A) prevents 
the Warburg effect and forces cancer 
cells to revert to oxidative phosphoryla-
tion in order to reoxidize NADH and pro-
duce ATP (Fantin et al., 2006; Shim et 
al., 1997). While the cells are respiratory 
competent, they exhibit attenuated tumor 
growth, suggesting that aerobic glycoly-
sis might be essential for cancer progres-
sion. In a primary fibroblast cell culture 
model of stepwise malignant transfor-
mation through overexpression of telom-
erase, large and small T antigen, and the 
H-Ras oncogene, increasing tumorige-
nicity correlates with sensitivity to glyco-
lytic inhibition. This finding suggests that 
the Warburg effect might be inherent to 
the molecular events of transformation 
(Ramanathan et al., 2005). However, the 
introduction of similar defined factors into 
human mesenchymal stem cells (MSCs) 
revealed that transformation can be asso-
ciated with increased dependence on 
oxidative phosphorylation (Funes et al., 
2007). Interestingly, when introduced in 
vivo these transformed MSCs do upreg-
ulate glycolytic genes, an effect that is 
reversed when the cells are explanted 
and cultured under normoxic conditions. 704 Cell 134, September 5, 2008 ©2008 Elsevier Inc.
These contrasting models suggest that 
the Warburg effect may be context depen-
dent, in some cases driven by genetic 
changes and in others by the demands 
of the microenvironment. Regardless of 
whether the tumor microenvironment or 
oncogene activation plays a more impor-
tant role in driving the development of a 
distinct cancer metabolism, it is likely that 
the resulting alterations confer adaptive, 
proliferative, and survival advantages on 
the cancer cell.
Altered Metabolism Provides 
 Substrates for Biosynthetic Pathways
Although studies in cancer metabolism 
have largely been energy-centric, rap-
idly dividing cells have diverse require-
ments. Proliferating cells require not 
only ATP but also nucleotides, fatty 
acids, membrane lipids, and proteins, 
and a reprogrammed metabolism may 
serve to support synthesis of macro-
molecules. Recent studies have shown 
that several steps in lipid synthesis are 
required for and may even actively pro-
mote tumorigenesis. Inhibition of ATP 
citrate lyase, the distal enzyme that 
converts mitochondrial-derived citrate 
into cytosolic acetyl coenzyme A, the 
precursor for many lipid species, pre-
vents cancer cell proliferation and tumor 
growth (Hatzivassiliou et al., 2005). 
Fatty acid synthase, expressed at low 
levels in normal tissues, is upregulated 
in cancer and may also be required for 
tumorigenesis (reviewed in Menendez 
and Lupu, 2007). Furthermore, can-
cer cells may also enhance their bio-
synthetic capabilities by expressing a 
tumor-specific form of pyruvate kinase 
(PK), M2-PK. Pyruvate kinase cata-
lyzes the third irreversible reaction of 
glycolysis, the conversion of phospho-
enolpyruvate (PEP) to pyruvate. Sur-
prisingly, the M2-PK of cancer cells is 
thought to be less active in the conver-
sion of PEP to pyruvate and thus less 
efficient at ATP production (reviewed in 
Mazurek et al., 2005). A major advan-
tage to the cancer cell, however, is that 
the glycolytic intermediates upstream 
of PEP might be shunted into synthetic 
processes. Recent work has found that 
the cancer-specific M2-PK causes an 
increase in the incorporation of glucose 
carbons into lipids and, expanding the 
connection between growth factor sig-
naling and cancer metabolism, may be 
regulated by phosphotyrosine binding 
(Christofk et al., 2008a, 2008b).
Making the building blocks of the cell, 
however, incurs an energetic cost and 
cannot fully explain the Warburg effect. 
Biosynthesis, in addition to causing an 
inherent increase in ATP demand in order 
to execute synthetic reactions, should 
also cause a decrease in ATP supply 
as various glycolytic and Krebs cycle 
intermediates are diverted. Lipid syn-
thesis, for example, requires the coop-
eration of glycolysis, the Krebs cycle, 
and the pentose phosphate shunt. As 
pyruvate must enter the mitochondria in 
this case, it avoids conversion to lactate 
and therefore cannot contribute to gly-
colysis-derived ATP. Moreover, whereas 
increased biosynthesis may explain the 
glucose hunger of cancer cells, it can-
not explain the increase in lactic acid 
production originally described by War-
burg, suggesting that lactate must also 
result from the metabolism of non-glu-
cose substrates. Recently, it has been 
demonstrated that glutamine may be 
metabolized by the citric acid cycle in 
cancer cells and converted into lactate, 
producing NADPH for lipid biosynthesis 
and oxaloacetate for replenishment of 
Krebs cycle intermediates (DeBerardinis 
et al., 2007).
Metabolic Pathways Regulate 
Apoptosis
In addition to involvement in proliferation, 
altered metabolism may promote another 
cancer-essential function: the  avoidance 
of apoptosis. Loss of the p53 target 
TIGAR sensitizes cancer cells to apopto-
sis, most likely by causing an increase in 
reactive oxygen species (Bensaad et al., 
2006). On the other hand, overexpression 
of glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) prevents caspase-inde-
pendent cell death, presumably by stimu-
lating glycolysis, increasing cellular ATP 
levels, and promoting autophagy (Colell 
et al., 2007). Whether or not GAPDH plays 
a physiological role in the regulation of 
cell death remains to be determined.
Intriguingly, Bonnet et al. (2007) have 
reported that treating cancer cells with 
dichloroacetate (DCA), a small molecule 
inhibitor of pyruvate dehydrogenase 
kinase, has striking effects on their sur-
vival and on xenograft tumor growth. 
DCA, a currently approved treatment 
for congenital lactic acidosis, activates 
oxidative phosphorylation and pro-
motes apoptosis by two mechanisms. 
First, increased flux through the elec-
tron transport chain causes depolar-
ization of the mitochondrial membrane 
potential (which the authors found to 
be hyperpolarized specifically in cancer 
cells) and release of the apoptotic effec-
tor cytochrome c. Second, an increase 
in reactive oxygen species generated by 
oxidative phosphorylation upregulates 
the voltage-gated K+ channel, leading to 
potassium ion efflux and caspase acti-
vation. Their work suggests that can-
cer cells may shift their metabolism to 
glycolysis in order to prevent cell death 
and that forcing cancer cells to respire 
aerobically can counteract this adapta-
tion. Although this preliminary work has 
prompted some cancer patients to self-
medicate with DCA, a controlled clini-
cal trial will be essential to demonstrate 
unequivocally the safety and efficacy of 
DCA as an anti-cancer agent.
Cancer Cells May Signal Locally in 
the Tumor Microenvironment
Cancer cells may rewire metabolic path-
ways to exploit the tumor microenviron-
ment and to support cancer-specific 
signaling. Without access to the central 
circulation, it is possible that metabolites 
can be concentrated locally and reach 
suprasystemic levels, allowing cancer 
cells to engage in metabolite-mediated 
autocrine and paracrine signaling that 
does not occur in normal tissues. So-
called androgen-independent prostate 
cancers may only be independent from 
exogenous, adrenal-synthesized andro-
gens. Androgen-independent prostate 
cancer cells still express the androgen 
receptor and may be capable of autono-
mously synthesizing their own andro-
gens (Stanbrough et al., 2006).
Perhaps the more provocative but as 
yet untested idea is that metabolites in 
the diffusion-limited tumor microenviron-
ment could be acting as paracrine signal-
ing molecules. Traditionally thought of as 
a glycolytic waste product, lactate may 
be one such signal. As noted above, it 
has been found that inhibition of lactate 
dehydrogenase can block tumor growth, 
most likely by multiple mechanisms. Much 
of the evidence for lactate as a multifunc-Cell 134, September 5, 2008 ©2008 Elsevier Inc. 705
tional metabolite comes from work in exer-
cise physiology and muscle metabolism 
(reviewed in Philp et al., 2005). Transported 
by several monocarboxylate transporters, 
lactate may be shared and metabolized 
among cells, although the idea is still con-
troversial (Hashimoto et al., 2006; Yoshida 
et al., 2007). The interconversion of lactate 
and pyruvate might alter the NAD+/NADH 
ratio in cells, and lactate exchange may 
serve to coordinate the metabolism of a 
group of cells. The tumor-stroma inter-
action may therefore have a metabolic 
component (Koukourakis et al., 2006). 
Cancer cells respond cell-autonomously 
to hypoxia to initiate angiogenesis, and so 
it would be exciting if a metabolite such as 
lactate could positively amplify this angio-
genic program, a process that requires a 
semicoordinated effort among multiple 
cells. Indeed, acidosis often precedes 
angiogenesis, and lactate may stimulate 
HIF expression independently of hypoxia 
(Fukumura et al., 2001; Lu et al., 2002; Shi 
et al., 2001). Cancer cells, by participating 
in a kind of quorum sensing and coordi-
nating their metabolism, may therefore act 
as a pseudo-organ.
Metabolism as an Upstream 
 Modulator of Signaling Pathways
Not only is metabolism downstream 
of oncogenic pathways, but an altered 
upstream metabolism may affect the 
activity of signaling pathways that nor-
mally sense the state of the cell. Individu-
als with inherited mutations in succinate 
dehydrogenase and fumarate hydratase 
develop highly angiogenic tumors, not 
unlike those exhibiting loss of the VHL 
tumor suppressor protein that acts 
upstream of HIF (reviewed in Kaelin and 
Ratcliffe, 2008). The mechanism of tum-
origenesis in these cancer syndromes is 
still contentious. However, it has been 
proposed that loss of succinate dehydro-
genase and fumarate hydratase causes 
an accumulation of succinate or fumar-
ate, respectively, leading to inhibition of 
the prolyl hydroxylases that mark HIF for 
VHL-mediated degradation (Isaacs et al., 
2005; Pollard et al., 2005; Selak et al., 
2005). In this rare case, succinate dehy-
drogenase and fumarate hydratase are 
acting as bona fide tumor suppressors.
Mutations in metabolic genes, how-
ever, need not be a cancer-causing 
event. More subtly, the activation of vari-
ous metabolic pathways might modulate 
the activity of downstream pro-cancer 
factors. Whereas it is well-accepted that 
growth factor signaling is commonly 
dysregulated in cancer, the involvement 
of nutrient or energy signaling in cancer 
remains unclear. In prokaryotes, various 
metabolites are sensed directly by the 
signaling machinery. The mammalian 
pathways that respond to energy and 
nutrient status may also interface with 
metabolites directly. It is well established 
that AMP-kinase senses the AMP/ATP 
ratio (reviewed in Hardie, 2007), whereas 
mTOR (the mammalian target of rapamy-
cin) senses cellular amino acid con-
centrations (Kim et al., 2008; Sancak et 
al., 2008). Both AMP-kinase and mTOR 
have been linked to tumor syndromes. 
It is possible that one way to upregulate 
these pro-growth signaling pathways 
is to increase the levels of the normal 
metabolites that they sense.
Metabolism Upregulation Generates 
Toxic Byproducts
Although altered metabolism confers 
several advantages on the cancer cell, it 
does not come without disadvantages. 
As a consequence of a deranged or sim-
ply overactive metabolism, cancer cells 
may be burdened with toxic byproducts 
that require disposal. So far, there is rela-
tively little evidence for this hypothesis in 
the existing literature, but a few exam-
ples do suggest that cancer cells require 
detoxification mechanisms to maintain 
survival. Although there are enzymes 
that detoxify exogenous toxins, sev-
eral “house-cleaning” enzymes, a term 
coined from studies in bacteria, deal with 
endogenous toxic metabolites (reviewed 
in Galperin et al., 2006). The best exam-
ple of “house-cleaning” enzymes are 
the NUDIX (noncanonical nucleoside 
diphosphate linked to some other moiety 
X) hydrolases, a family of enzymes that 
act on the nucleotide pool and remove 
noncanonical nucleoside triphosphates. 
When incorporated into the DNA, these 
aberrant nucleotides can lead to mis-
matches, mutations, and eventually 
cell death. The dUTP pyrophosphatase 
(DUT), which hydrolyzes dUTP to dUMP 
and prevents the incorporation of uracils 
into DNA, may play a role in resistance 
to thymidylate synthase inhibitors. Sup-
pression of DUT sensitizes some can-
cer cells to pyrimidine antimetabolites, 
suggesting that inhibition of these cel-
lular house-cleaning enzymes may be 
an effective adjunct chemotherapeutic 
strategy (Koehler and Ladner, 2004).
The lactate production associated with 
the shift to a glycolytic metabolism is 
thought to contribute to the acidification 
of the microenvironment. Able to adapt 
to and even benefit from an acidic envi-
ronment, cancer cells have been shown 
to upregulate vacuolar H+-ATPases, 
Na+-H+ antiporters, and H+-linked mono-
carboxylate transporters (reviewed in 
Gatenby and Gillies, 2004). Inhibition of 
these adaptive mechanisms can lead to 
decreased viability of cancer cells and 
increased sensitivity to chemotherapeu-
tic agents (reviewed in Fais et al., 2007; 
Fang et al., 2006).
Uncharted Territory
Many mysteries remain unsolved in our 
understanding of even normal human 
metabolism, let alone that of cancer cells. 
The metabolic pathways of the mamma-
lian cell and their many interconnections 
are incomplete, as many enzymes remain 
unannotated in the human genome. 
Although we have guesses by homology, 
the identities of the human enzymes that 
catalyze reactions we know must occur 
are still elusive. In addition to annotating 
all human metabolic genes, the “ins” and 
the “outs” (i.e., the metabolites that enter 
and exit cells) should be measured and 
cataloged. It is also entirely unclear what 
percentage of the cellular fuel is normally 
used for ATP generation, biosynthesis, or 
other processes. And with few exceptions 
surprisingly little is known about intercel-
lular metabolism. Much of our understand-
ing of metabolism has been inherited from 
work in simple organisms; the compart-
mental nature of human metabolism is an 
exciting area of potential exploration.
Although aerobic glycolysis is the 
most characterized, although still puz-
zling, metabolic phenomenon in cancer, 
many other aspects of cancer metabo-
lism are likely to be derangements of 
normal metabolism and ought to be elu-
cidated. The nutrient conditions of the 
tumor microenvironment have not yet 
been carefully examined. Cancer cells, 
despite engaging in energy-costly pro-
cesses, must still be able to maintain ATP 
levels, by either relying on increased flux 706 Cell 134, September 5, 2008 ©2008 Elsevier Inc.
through glycolysis or utilizing a diversity 
of fuel sources. Several hypotheses exist 
as to why a fraction of tumors are refrac-
tory to imaging by FDG-PET. One pos-
sibility is that certain cancer cells may 
not be primarily glucose-metabolizers 
but may rely on alternative fuel sources, 
the detailed characterization of which 
may lead to the detection and treatment 
of “PET-negative” tumors. Furthermore, 
there are more complex questions to 
be answered: Is it possible that cancer 
cells exhibit “metabolite addiction”? Are 
there unique cancer-specific metabolic 
pathways, or combinations of pathways, 
utilized by the cancer cell but not by nor-
mal cells? Are different stages of meta-
bolic adaptations required for the cancer 
cell to progress from the primary tumor 
stage to invasion to metastasis? How 
malleable is cancer metabolism?
From a therapeutic perspective, 
knowledge of the causes, benefits, and 
vulnerabilities of cancer cell metabolism 
will enable the identification of new drug 
targets and will facilitate the design of 
metabolite mimetics that are uniquely 
taken up by cancer cells or converted 
into the active form by enzymes upregu-
lated in tumors. Profiling of either metab-
olites or enzymatic activities may allow 
us to develop diagnostic tests of can-
cer, and metabolite derivatives can be 
used for the molecular imaging of can-
cer, as exemplified by FDG-PET. We find 
the possibility of a new class of cancer 
therapeutics and diagnostic tools espe-
cially exciting. Therefore, we emphasize 
the need to explore beyond a glucose 
and energy-centric driven model of can-
cer metabolism to a broader one that 
encompasses all of the metabolic needs 
of a cancer cell. Perhaps it is time to step 
out from under Warburg’s shadow.
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